Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)-Reference-Cited by-同舟云学术

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)

Published:2018-12 Issue: Volume:105 Page:41-49
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Saeki Hiroshi,Oki Eiji,Kashiwada Tomomi,Arigami Takaaki,Makiyama Akitaka,Iwatsuki Masaaki,Narita Yukiya,Satake Hironaga,Matsuda Yoshiko,Sonoda Hideto,Shimokawa Mototsugu,Maehara Yoshihiko

Funder

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical Co., Ltd, Japan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target;Gravalos;Ann Oncol,2008

2. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab;Tanner;Ann Oncol,2005

3. Assessment of a HER2 scoring system for gastric cancer: results from a validation study;Hofmann;Histopathology,2008

4. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas;Cho;Pathology,2012

5. Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer;Kimura;Anticancer Res,2014

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09

2. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies;Cancers;2024-08-15

3. Advances in the treatment of human epidermal growth factor receptor 2-positive gastric cancer;International Journal of Clinical Oncology;2024-07-31

4. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22

5. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms;Blood;2024-07-11